Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Biotech Partners to Focus on Drugs Targeting G-Protein Coupled Receptors

By BiotechDaily International staff writers
Posted on 05 Nov 2012
An agreement between the French company Domain Therapeutics (Illkirch-Strasbourg, France) and Japanese Ono Pharmaceutical Co., Ltd. (Osaka, Japan) is designed to promote the discovery of small molecules targeting G-Protein Coupled Receptors (GPCRs).

GPCRs are not only the largest protein family in the human genome but also the single biggest target for therapeutic agents. Ligand binding to these receptors activates their associated G protein, which then activates an effector enzyme to generate an intracellular second messenger. All GPCRs contain seven membrane-spanning regions with their N-terminal segment on the external face and their C-terminal segment on the cytosolic face of the plasma membrane. This large receptor family includes light-activated receptors (rhodopsins) in the eye and thousands of odorant receptors in the nose, as well as numerous receptors for various hormones and neurotransmitters. Although these receptors are activated by different ligands and may mediate different cellular responses, they all mediate a similar signaling pathway.

Under the terms of the collaborative agreement for development of GPRC-directed drugs, Ono Pharmaceutical will provide Domain Therapeutics with an upfront payment and provide research funding for collaborative research programs and success-based milestones. Domain Therapeutics will receive royalties on sales of the products.

Domain Therapeutics will apply its proprietary DTect-All GPCR drug discovery platform and utilize its expertise in GPCR medicinal chemistry and pharmacology to design and optimize small molecules into drug candidates having activity against GPCRs selected by Ono Pharmaceutical.

Ono Pharmaceutical will then have worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration.

“This collaboration with Ono further confirms the value of our differentiated drug discovery process and of our expertise in the field of GPCRs. It constitutes an important step towards the objective of Domain Therapeutics to collaborate with pharma partners on integrated projects, from target to drug candidate,” said Pascal Neuville, CEO of Domain Therapeutics. “We are delighted to be collaborating with Ono, which is recognized as a leading Japanese pharmaceutical company.”

Dr. Kazuhito Kawabata, executive director of discovery and research at Ono Pharmaceutical, said, “We highly appreciate Domain Therapeutics’ DTect-All technology and strongly believe that the company is the partner of choice to identify GPCR drugs. This collaboration will strengthen Ono’s drug discovery capability in research areas of Ono’s expertise with significant unmet medical needs. We are expecting that innovative drugs will be created through this collaboration.”

Related Links:

Ono Pharmaceutical
Domain Therapeutics


Channels

Genomics/Proteomics

view channel
Image: The osteochondroretricular stem cell is a newly identified type of bone stem cell that appears to be vital to skeletal development and may provide the basis for novel treatments for osteoarthritis, osteoporosis, and bone fractures. In this illustration of the head of a femur, osteochondroretricular stem cells are visualized in red (Photo courtesy of Dr. Timothy Wang, Columbia University).

Gremlin 1 Expression Distinguishes Stem Cells Able to Regenerate Bones and Cartilage in Adult Mice

A newly identified type of stem cell in the bone marrow of adult mice was found to be capable of regenerating both bone and cartilage. Investigators at Columbia University (New York, NY, USA) reported... Read more

Drug Discovery

view channel

Curcumin Used to Treat Alzheimer’s Disease

Curcumin, a natural substance found in the spice turmeric, has been used by many Asian cultures for centuries. Now, new research suggests that a close chemical analog of curcumin has properties that may make it useful as a treatment for Alzheimer’s disease. “Curcumin has demonstrated ability to enter the brain, bind... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.